Grifols stock steadies on 2025 revenue and debt metrics

Grifols stock ties its case to 2025 revenue, EBITDA, and net debt figures from the latest investor materials, with the share story framed by the companys balance sheet and operating scale.

Grifols stock (ES0171996087) is anchored by the latest reported 2025 numbers: revenue reached EUR 7.64 billion, adjusted EBITDA was EUR 1.63 billion, and net debt stood at EUR 8.8 billion at year-end 2025. The figures come from Grifols investor materials and frame the shares around scale, margin, and leverage rather than a single short-term catalyst.

EUR 7.64 billion revenue

Revenue of EUR 7.64 billion in 2025 gives the market a clear baseline for the Spanish plasma group, while adjusted EBITDA of EUR 1.63 billion shows the operating profit pool behind that scale. Net debt of EUR 8.8 billion at 31 December 2025 remains the key balance-sheet number for investors watching financial flexibility.

The comparison matters because the year-end debt figure and the EBITDA base belong to the same reporting period, allowing leverage to be read in context rather than in isolation. A stock story built on plasma collection and specialty medicines depends on whether earnings growth can outpace debt service over time.

Debt and margin matter

For Grifols stock, the more relevant lens is the combination of 2025 revenue, EBITDA, and net debt, because that trio defines both earnings power and financing pressure. The companys latest investor presentation also places the business within a global plasma market that rewards consistent supply and disciplined capital use.

A second reference point is the 2025 reporting year itself: the numbers are not a one-off quarter but a full-year base that investors can compare against future guidance and later reports. That makes the next set of results more important than headlines alone.

Plasma scale drives products

Grifols builds its business around plasma-derived medicines, and that product base is what turns the 2025 revenue number into an operating story. The revenue and EBITDA figures matter because they show how much money the company can generate before the balance sheet becomes the main constraint.

The market will keep comparing future reports with the 2025 base of EUR 7.64 billion revenue and EUR 1.63 billion adjusted EBITDA. If later updates improve leverage from the EUR 8.8 billion net debt level, the same full-year figures will become the reference point for a cleaner rerating argument.

Year-end leverage set

Grifols stock is quoted on the Spanish market under a euro-denominated listing structure, and its business remains closely tied to full-year operating execution. The 2025 debt figure of EUR 8.8 billion is the number that investors will continue to track alongside margins and cash generation.

As of 19 July 2026, the latest solid evidence set for Grifols is still the 2025 reporting base, which combines EUR 7.64 billion in revenue, EUR 1.63 billion in adjusted EBITDA, and EUR 8.8 billion in net debt. That is enough to define the shares around profitability, leverage, and follow-through from management.

Grifols product focus

The companys core product set is plasma-derived medicines, which is the business line that links collection volumes, processing capacity, and pharmaceutical demand. For investors, the value of that portfolio shows up in the 2025 revenue and EBITDA numbers rather than in product branding alone.

Grifols stock closing view

As of 19 July 2026, the stock level is best read against the full-year 2025 operating base rather than a fresh intraday quote. Grifols stock therefore remains a leverage-and-earnings story, with EUR 7.64 billion revenue, EUR 1.63 billion adjusted EBITDA, and EUR 8.8 billion net debt defining the current frame.

Grifols fact box

• Company: Grifols, S.A.
• ISIN: ES0171996087
• Price (as of 19 July 2026): not included
• Market capitalization: not included
• Sector / Industry: Health Care / Biotechnology
• Index membership: IBEX 35